Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.
Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, Saabye MJ, Barks JL, Kishore N, Morris DL. · 2010
Read Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. by Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, Saabye MJ, Barks JL, Kishore N, Morris DL. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2928212.txt.
Introduction
Meyer and colleagues reported a 2010 rat study of CP-690,550, a drug that blocks Janus kinases JAK1 and JAK3 and was then in trials for rheumatoid arthritis. Human trials had shown falling neutrophil counts during treatment, and the team wanted to link that drop to kinase selectivity.
Lab assays showed strong blocking of JAK1 and JAK3 signalling, with far weaker action through JAK2 in cells. In rats with adjuvant-driven joint disease, oral doses eased paw swelling in a dose-linked way. At helpful exposures the drug also brought raised blood cytokines, neutrophils, and marrow precursor cells back toward normal.
Catalog record
| CREATOR | Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, Saabye MJ, Barks JL, Kishore N, Morris DL. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis By Debra M Meyer, Michael I Jesson, Xiong Li, Mollisa M Elrick, Christie L Funckes-Shippy, James D Warner, Cindy J Gross, Martin E Dowty, Shashi K Ramaiah, Jeffrey L Hirsch, Matthew J Saabye, Jennifer L Barks Published in: Journal of Inflammation (London, England) DOI: 10.1186/1476-9255-7-41 ABSTRACT Background The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors. CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications. In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment. These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment. Methods Potency and selectivity of CP-690,550 for mouse, rat and human JAKs was evaluated in a panel of in vitro assays. The effect of CP-690,550 on granulopoiesis from progenitor cells was also assessed in vitro using colony forming assays. In vivo the potency of orally administered CP-690,550 on arthritis (paw edema), plasma cytokines, PBNC and bone marrow differentials were evaluated in the rat adjuvant-induced arthritis (AIA) model. Results CP-690,550 potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2 in cellular assays, despite inhibiting all four JAK isoforms with nM potency in in vitro enzyme assays. Dose-dependent inhibition of paw edema was observed in vivo with CP-690,550 treatment. Plasma cytokines (IL-6 and IL-17), PBNC, and bone marrow myeloid progenitor cells were elevated in the context of AIA disease. At efficacious exposures, CP-690,550 returned all of these parameters to pre-disease levels. The plasma concentration of CP-690,550 at efficacious doses was above the in vitro whole blood IC50 of JAK1 and JAK3 inhibition, but not that of JAK2. Conclusion Results from this investigation suggest that CP-690,550 is a potent inhibitor of JAK1 and JAK3 with potentially reduced cellular potency for JAK2. In rat AIA, as in the case of human RA, PBNC were decreased at efficacious exposures of CP-690,550. Inflammatory end points were similarly reduced, as judged by attenuation of paw edema and cytokines IL-6 and IL-17. Plasma concentration at these exposures was consistent with inhibition of JAK1 and JAK3 but not JAK2. Decreases in PBNC following CP-690,550 treatment may thus be related to attenuation of inflammation and are likely not due to suppression of granulopoiesis through JAK2 inhibition. BACKGROUND CP-690,550, a selective inhibitor of the JAK family of protein tyrosine kinases, is being developed as an immunosuppressive and anti-inflammatory agent for the treatment and prevention of acute allograft rejection, RA, psoriasis and other immune mediated diseases [1-6]. In clinical trials, CP-690,550 administration resulted in a dose-related decrease in PBNCs in active RA patients [7,8] within 2 weeks of treatment, but not in psoriasis patients [9], renal allograft patients [10] or normal volunteers [11] for up to 14 and 28 days of treatment, respectively. In the RA trial [7,8], as observed in other RA studies [12], patients were found to have baseline PBNCs which were at or above the upper limit of the reference range for normal human subjects. Following treatment with CP-690,550 for 2 weeks, PBNCs in these patients were found to decrease to within the normal reference range, and showed a strong dose-related correlation with the anti-inflammatory activity of the compound [13]. Multiple inflammatory cytokine receptors signal through pathways involving JAK1 and JAK3, and their inhibition with CP-690,550 likely leads to anti-inflammatory and immunosuppressive activity. Conversely, JAK2 is required for signaling through several growth factor receptors and is important for myeloid and erythroid hematopoiesis [14-16]. The aim of the current study was to characterize the potency and selectivity of CP-690,550 for the JAK family members and to determine if PBNC reductions in the context of arthritis are related to the anti-inflammatory efficacy of CP-690,550 (through JAK 1 and JAK3 inhibition), or due to inhibition of hematopoiesis through inhibition of JAK2 at efficacious exposures. The in vitro potency and selectivity of CP-690,550 were determined using recombinant human kinases and whole blood cytokine induced STAT phosphorylation assays. In studies published previously, CP-690,550 was shown to inhibit arthritis development and bone destruction in the rat AIA model [17]. In the current study, rat AIA was used to characterize the in vivo effects of inflammation and CP-690,550 treatment on PBNCs and bone marrow myeloid progenitors, and in vitro bone marrow progenitor cell differentiation assays were used to determine the direct effects of CP-690,550 on granulopoiesis. Additionally, pharmacokinetic and pharmacodynamic modeling was used to determine the drug concentration-effect relationship between JAK kinase inhibition and neutrophil reductions in the non-clinical and clinical studies. Results of this study suggest that the CP-690,550 mediated reduction in PBNCs in the rat AIA model, and likely in human RA patients, is due to the anti-inflammatory action of the compound by the suppression of cytokines and chemotactic factors which elevate neutrophil counts in the peripheral compartment. METHODS Enzyme Potency and Selectivity Assays Recombinant kinase domains of JAK2 and JAK3 were purchased from Invitrogen (Madison, WI), and recombinant GST-fusions of JAK1 (residues 852-1142) and TYK2 (residues 870-1187, containing a C1187 S modification) kinase domains were expressed and purified at Pfizer Laboratories. MgATP was obtained from Sigma Chemical Company (St. Louis, MO). JAKtide (FITC-KGGEEEEYFELVKK) and IRS-1 (5-FAM-KKSRGDYMTMQIG) peptides were purchased from American Peptide Company (Sunnyvale, CA). FITC-conjugated antibodies against human CD8, mouse CD8, mouse CD11b and rat CD3; PE-conjugated antibodies against human CD3, human CD14, mouse CD3 and rat CD4; and AlexaFluor®647 (Ax647) conjugated pSTAT1, pSTAT3, pSTAT5 and pSTAT6 monoclonal antibodies were from BD Biosciences (San Jose, CA). The PE-conjugated antibody against mouse F4/80 was from eBioscience (San Diego, CA). Recombinant human, mouse and rat cytokines were from R&D Systems (Minneapolis, MN). In Vitro Kinase Assays A peptide mobility shift assay was used to quantify the phosphorylation of JAKtide (for JAK2 and JAK3) or IRS-1 (for JAK1 and TYK2) peptide substrates. Endpoint reactions were carried out at the apparent Km (MgATP) for each enzyme (4 μM for JAK2 and JAK3, 40 μM for JAK1 and 7 μM for TYK2) in the presence of CP-690,550 and 1 μM substrate. Samples were analyzed by LabChip 3000 from Caliper Life Sciences (Hopkinton, MA). Data was analyzed using HTS Well Analyzer Software from Caliper Life Sciences to determine the amount of product formed, and was expressed as percent of control activity based on uninhibited and no enzyme controls. Dose-response data were fit using 4 parameter logistic fit software to determine IC50. To determine the inhibition constant (Ki) for each enzyme, initial velocities were measured at varying concentrations of CP-690,550 and MgATP. The data from each experiment were fit to competitive, noncompetitive and uncompetitive inhibition models, to determine nonlinear fit and Lineweaver-Burk transformations [18]. In Vitro Whole Blood STAT Phosphorylation Assays Heparinized normal human, DBA/1 mouse or Lewis rat whole blood was pre-incubated with CP-690,550 for 1 hour and stained with lineage-specific antibodies. Specifically, species-specific antibodies to CD3 and CD8 were used to identify human, mouse and rat total T cells or the CD8 subset, while anti-CD14 was used to label human monocytes, anti-CD11b and anti-F4/80 were used to label mouse monocytes,